A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis (Q33399980)

26 July 2017

title

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis (English)

1 reference

26 July 2017

0 references

1 reference

ChEBI release 2020-05-28

ChEBI ID

66919

placebo-controlled trial

1 reference

1 reference

Vikas Gupta

5

0 references

Srdan Verstovsek

1

object named as

Srdan Verstovsek

1 reference

26 July 2017

15

Elizabeth Hexner

1 reference

26 July 2017

Ruben A Mesa

2

1 reference

26 July 2017

Jason Gotlib

3

1 reference

26 July 2017

Richard S Levy

4

1 reference

26 July 2017

John F DiPersio

6

1 reference

26 July 2017

John V Catalano

7

1 reference

26 July 2017

Michael Deininger

8

1 reference

26 July 2017

Carole Miller

9

1 reference

26 July 2017

Richard T Silver

10

1 reference

26 July 2017

Moshe Talpaz

11

1 reference

26 July 2017

Elliott F Winton

12

1 reference

26 July 2017

Jimmie H Harvey

13

1 reference

26 July 2017

Murat O Arcasoy

14

1 reference

26 July 2017

Roger M Lyons

16

1 reference

26 July 2017

Ronald Paquette

17

1 reference

26 July 2017

Azra Raza

18

1 reference

26 July 2017

Kris Vaddi

19

1 reference

26 July 2017

Susan Erickson-Viitanen

20

1 reference

26 July 2017

Iphigenia L Koumenis

21

1 reference

26 July 2017

William Sun

22

1 reference

26 July 2017

Victor Sandor

23

1 reference

26 July 2017

Hagop M Kantarjian

24

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 March 2012

1 reference

The New England Journal of Medicine

26 July 2017

published in

1 reference

26 July 2017

volume

366

1 reference

26 July 2017

issue

9

1 reference

26 July 2017

page(s)

799-807

1 reference

Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822164

Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822164

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822164

Molecular aspects of myeloproliferative neoplasms.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822164

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822164

Primary myelofibrosis: update on definition, pathogenesis, and treatment.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822164

JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822164

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822164

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822164

Toxicity and response criteria of the Eastern Cooperative Oncology Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822164

Splenic volume measurements on computed tomography utilizing automatically contouring software and its relationship with age, gender, and anthropometric parameters.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822164

Determination of normal splenic volume on computed tomography in relation to age, gender and body habitus.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4822164

Estimation of spleen volume using MR imaging and a random marking technique

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22375971

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22375971

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1056/NEJMOA1110557

1 reference

26 July 2017

1 reference

26 July 2017

1 reference